March 2008
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p63
This section offers news briefs of interest in the field of hematology. A contract was awarded by the National Cancer Institute (NCI) to SRI International, an independent nonprofit research and development organization, to conduct chemistry evaluations of anti-cancer drugs and dosage formulations. The Wallace H. Coulter Award for Lifetime Achievement in Hematology was established by the American Society of Hematology and the Wallace H. Coulter Foundation. An expanded cancer research program was created by the New York-Presbyterian Hospital.


Related Articles

  • Are We Training Our Fellows Adequately in Delivering Bad News to Patients? A Survey of Hematology/Oncology Program Directors. Hebert, Hannah D.; Butera, James N.; Castillo, Jorge; Mega, Anthony E. // Journal of Palliative Medicine;Dec2009, Vol. 12 Issue 12, p1119 

    Background: Medical oncologists often must deliver bad news. The authors were interested in the extent of formal training in delivering bad news in hematology/oncology fellowships in the United States. Methods: An e-mail survey was sent to all hematology/oncology fellowship program directors in...

  • BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase. Larsen, Stig; Butthongkomvong, Kritiya; Manikhas, Alexey; Trishkina, Ekaterina; Poddubuskaya, Elena; Matrosova, Marina; Srimuninnimit, Vichien; Lindkær-Jensen, Steen // Breast Cancer: Targets & Therapy;2014, Vol. 6, p179 

    The aims were to compare the efficacy and tolerability of a new benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride (BP-C1) versus placebo and to investigate the long-term tolerability of BP-C1 in the treatment of patients with metastatic breast cancer. Material and...

  • Estado nutricio en pacientes de primer ingreso a hospitalización del Servicio de Hematología del Instituto Nacional de Cancerología. Baltazar Luna, E.; Omaña Guzmán, L. I.; Ortiz Hernández, L.; Ñamendis-Silva, S. A.; De Nicola Delfín, L. // Nutricion Hospitalaria;jul/ago2013, Vol. 28 Issue 4, p1259 

    Objectives: To determine the nutritional status of patients admitted to hospital for the first time the hematology service and who have not received treatment for cancer, to know if the nutritional status assessed by the EGS-GP and serum albumin related mortality of patients Methods; A...

  • PDS BIOTECHNOLOGY AWARDED $1.28M NATIONAL CANCER CONTRACT.  // Biotech Business;Apr2010, Vol. 23 Issue 4, p7 

    The article announces the 1.28 million U.S. dollar phase 2 SBIR contract received by PDS Biotechnology Corp. from the National Cancer Institute Division of the U.S. National Institute of Health. Under the terms of the contract, funding will be allocated to complete studies required to file an...

  • Grants roundup.  // Medical Device Daily;11/10/2010, Vol. 14 Issue 219, p3 

    The article reports on a Phase I Small Business Innovation Research (SBIR) contract awarded to Insight Genetics from the National Cancer Institute (NCI) for the development of a new test for lung cancer patients.

  • Agreements/contracts.  // Medical Device Daily;12/7/2009, Vol. 13 Issue 234, p4 

    The article reports on a contract awarded by the National Cancer Institute to Fred Hutchinson Cancer Research Center to become the sole operator of its Cancer Information Service (CIS) Contact Center in the U.S. The contract will reportedly create 60 new jobs at the center, which is scheduled to...

  • Celek Pharmaceuticals Receives National Cancer Institute Award to Develop CEL- 031 for the Treatment of Bladder Cancer.  // Biomedical Market Newsletter;12/28/2011, Vol. 21, p1 

    The article reports that Celek Pharmaceuticals LLC. has signed a contract with National Cancer Institute (NCI) in the U.S for the development of CEL-031 an oncology drug used for the treatment of bladder cancer. Drug induces apoptosis in human tumor cells in which phosphodiesterase enzymes...

  • Micromet Signs CRADA with National Cancer Institute to Expand Development of Blinatumomab.  // Biomedical Market Newsletter;1/14/2012, Vol. 21, p1 

    The article presents information on a cooperative research and development agreement signed by Micromet inc. with the National Cancer Institute to expand development of blinatumomab in patients suffering from acute lymphoblastic leukemia and various sub-types of lymphoma. It describes...

  • Morphotek and NCI to develop antibodies for treatment of pancreatic, ovarian and lung cancer.  // PharmaWatch: Biotechnology;February 2004, Vol. 3 Issue 2, p13 

    Reports on the signed agreement between Morphotek Inc. with the National Cancer Institute on producing therapeutic antibodies to an undisclosed cancer-associated protein. Application of Morphotek's proprietary Morphodoma antibody technology to the development of antibodies for treating...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics